Celcuity Inc. is a publicly listed (NASDAQ: CELC) clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy. Our mission is to extend the lives of cancer patients by leveraging our proprietary CELsignia platform to develop first-in-class therapies and companion diagnostics.
Celcuity’s lead therapeutic candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTOR inhibitor. Celcuity is currently planning to initiate a Phase 3 registration-enabling clinical trial to evaluate gedatolisib as a potential first-in-class treatment for patients with ER+/HER2-negative metastatic breast cancer. Our CELsignia companion diagnostics are currently being evaluated in five clinical trials to assess whether breast cancer patients identified with a CELsignia test respond to a matching targeted therapy.
Data Provided by Quotemedia with delay
There are currently no events to display.
August 10, 2022 at 11:30 AM ET
August 11, 2022 at 4:30 PM ET
June 1, 2022
19th Annual Craig-Hallum Institutional Investor Conference
June 9, 2022 at 2:30 PM ET
Jefferies Healthcare Conference
May 16, 2022 at 4:30 PM ET
Celcuity First Quarter 2022 Financial Results Webcast/Conference Call
March 23, 2022 at 4:30 PM ET
Celcuity Fourth Quarter and Full Year 2021 Financial Results Conference Call